Cardinal Health Inc. ($CAH) Stock Forecast: Down 3.0% Today

What is Cardinal Health Inc.?

Cardinal Health (CAH) is a multinational healthcare services company that specializes in the distribution of pharmaceuticals and medical products, with a focus on improving the cost-effectiveness of healthcare. Today, CAH experienced a strong bearish movement in the stock market.

Why is Cardinal Health Inc. going down?

CAH stock is down 3.0% on Dec 2, 2025 17:26

• The bearish movement in Cardinal Health's stock today could be attributed to various factors:
• Despite the company's increased operating earnings, the recent revenue dip might have raised concerns among investors about its growth prospects.
• The acquisition announcement and year-end results reporting might have not met market expectations, leading to a negative sentiment towards the stock.
• The overall market sentiment towards healthcare stocks or specific developments within the healthcare sector could have influenced the bearish movement in CAH's stock price.
• Investors might be reevaluating Cardinal Health's financial stability and growth potential in comparison to other highlighted stocks with strong interest coverage ratios.
• The focus on financial metrics like the Price-to-Earnings ratio and valuation scores in discussions about other companies could have also shifted investor attention away from Cardinal Health, impacting its stock performance negatively.

CAH Price Chart

CAH Technical Analysis

CAH News

Zacks.com featured highlights include Life Time, Cardinal Health, LeMaitre Vascular and Flowserve

Zacks.com highlights four stocks—Life Time, Cardinal Health, LeMaitre Vascular, and Flowserve—possessing high interest coverage ratios, signaling strong financial stability for investors heading into 2026. The article explains the importance of the interest coverage ratio as a critical indicator of a company's ability to meet financial obligations amid market uncertainties. Each highlighted company's recent performance metrics and Zacks Rank are provided, advocating for deeper financial evaluation beyond just headline figures.

https://finance.yahoo.com/news/zacks-com-featured-highlights-life-150200909.html

CAH SEC Filings - Cardinal Health Inc 10-K, 10-Q, 8-K Forms

This page provides an overview of Cardinal Health (CAH) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-powered summaries and real-time alerts for insider transactions. Recent filings detail performance-based share awards to key executives, a Form S-3 shelf prospectus, and fiscal year 2025 financial results showing increased operating earnings despite a revenue dip. The company also announced an acquisition and year-end results reporting.

https://www.stocktitan.net/sec-filings/CAH/page-5.html

Is There Opportunity in Henry Schein After 18% Rally and Digital Dentistry Expansion?

Henry Schein's stock recently rallied 18%, sparking debate on its future growth and risk. The company shows a strong valuation score of 5 out of 6 according to Simply Wall St's valuation checks, and a Discounted Cash Flow (DCF) analysis suggests it is significantly undervalued by 57.2%. Its Price-to-Earnings (PE) ratio is currently 22.45x, suggesting it is about fairly valued when compared to its tailored "Fair Ratio" of 24.99x.

https://simplywall.st/stocks/us/healthcare/nasdaq-hsic/henry-schein/news/is-there-opportunity-in-henry-schein-after-18-rally-and-digi

Cardinal Health ( CAH ) Is Up 2.00% in One Week: What You Should Know

Does Cardinal Health (CAH) have what it takes to be a top stock pick for momentum investors? Let's find out.

https://www.zacks.com/stock/news/2796732/cardinal-health-cah-is-up-200-in-one-week-what-you-should-know

Angiostomy Cannula Market to Get an Explosive Growth | Edwards

The Angiostomy Cannula Market is projected to reach USD 322.7 million by 2032, growing at a CAGR of 6.9% from 2025. A new report by Coherent Market Insights offers an in-depth analysis of the market, including growth drivers, restraints, competitive landscape, and regional forecasts. Key players include Edwards Lifesciences Corporation, Medtronic, and Merck & Co. Inc.

https://www.openpr.com/news/4291362/angiostomy-cannula-market-to-get-an-explosive-growth-edwards

Trending Today

Monero ($XMR) Crypto Forecast: Up 6.8% Today

Ethereum ($ETH) Crypto Forecast: Up 6.8% Today

Solana ($SOL) Crypto Forecast: Up 5.6% Today

Silver ($XAG) Commodity Forecast: Up 5.5% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.0% Today

ZCash ($ZEC) Crypto Forecast: Up 9.3% Today

dogwifhat ($WIF) Crypto Forecast: Up 10.7% Today

Fetch.ai ($FET) Crypto Forecast: Up 8.5% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Up 5.1% Today

Instacart (Maplebear Inc) ($CART) Stock Forecast: Up 5.5% Today

Cardinal Health Inc. Price History

31.00.2025 - CAH Stock was down 5.4%

• CAH reported strong Q2 earnings and sales that exceeded expectations, with an increase in the 2025 EPS view. Still, the negative impact of the OptumRx contract expiry on Pharmaceutical segment sales likely contributed to the bearish movement.
• The news of a Congress member buying up to $15K in Cardinal Health stock may have added some uncertainty or negative sentiment to the market, influencing the stock's downward trend.
• Despite solid revenue growth in the Other segment and increased sales in branded and specialty pharmaceuticals, concerns about the OptumRx contract expiry and supply-chain challenges may have overshadowed positive developments.
• Investors may approach Cardinal Health cautiously due to recent events and uncertainties surrounding the company's key segments and contracts.

06.00.2025 - CAH Stock was down 1.3%

• Despite CAH's strong quarterly results and robust product portfolio, the stock experienced a -1.02% decline in the most recent trading session.
• The market movement could be attributed to profit-taking by investors after a period of growth, leading to a temporary dip in the stock price.
• Investors might be reacting to broader market trends or sector-specific news impacting healthcare companies, causing a negative sentiment towards CAH in today's trading.

30.00.2025 - CAH Stock was up 0.0%

• The positive anticipation surrounding its upcoming Q2 earnings report, with growth in branded and specialty pharmaceutical sales expected to drive performance, could be a factor in the recent bullish movement in CAH.
• Market sentiment might have been influenced by a Congress member's purchase of Cardinal Health stock, signaling confidence in the company's future prospects.
• Contributing to the upward momentum in CAH's stock price could be the overall bullish trend in the market and the company hitting a 52-week high.

04.03.2025 - CAH Stock was down 5.6%

• CAH stock fell by 1.14% in the latest trading session.
• This downward movement could be related to market volatility or negative factors affecting the healthcare industry.
• Investors may be responding to worries about regulatory adjustments or changes in consumer healthcare demands.
• Traders should stay updated on company-specific updates and broader market patterns when considering CAH's stock.

02.11.2025 - CAH Stock was down 3.0%

• The bearish movement in Cardinal Health's stock today could be attributed to various factors:
• Despite the company's increased operating earnings, the recent revenue dip might have raised concerns among investors about its growth prospects.
• The acquisition announcement and year-end results reporting might have not met market expectations, leading to a negative sentiment towards the stock.
• The overall market sentiment towards healthcare stocks or specific developments within the healthcare sector could have influenced the bearish movement in CAH's stock price.
• Investors might be reevaluating Cardinal Health's financial stability and growth potential in comparison to other highlighted stocks with strong interest coverage ratios.
• The focus on financial metrics like the Price-to-Earnings ratio and valuation scores in discussions about other companies could have also shifted investor attention away from Cardinal Health, impacting its stock performance negatively.

03.09.2025 - CAH Stock was down 3.7%

• Cardinal Health (CAH) may have faced a downward trend due to its underperformance relative to other medical stocks like Arcutis Biotherapeutics (ARQT).
• The subdued performance of CAH in the healthcare industry this year might be linked to the market's negative movement.
• Investors could be turning their attention towards more promising opportunities in the medical field, resulting in a sell-off of CAH shares.
• Contrasting with ARQT's strong showing could have revealed weaknesses in CAH's finances or growth prospects, prompting investors to review their positions and contributing to the bearish trend.

12.07.2025 - CAH Stock was down 7.3%

• There has been bullish options activity indicating positive sentiment from investors, although this did not result in a positive stock movement.
• The company exceeded earnings estimates and raised EPS guidance for 2026, leading to a stock drop potentially linked to concerns about the expiration of the OptumRx contract and its impact on Pharmaceutical segment sales.
• The upcoming release of Q4 earnings may have caused stock price volatility as investors reacted to forecast changes and dividend income strategies.
• A comparison with Adaptive Biotechnologies in the medical sector suggests that market dynamics and company-specific factors could have influenced Cardinal Health's bearish performance despite positive developments.

12.07.2025 - CAH Stock was down 12.2%

• The bearish movement in CAH stock could be attributed to investors' concerns about the upcoming earnings report falling short of expectations.
• Discussion about earning $500 a month from CAH stock might have raised unrealistic expectations among investors, leading to disappointment when the stock did not perform as anticipated.
• A comparison with Adaptive Biotechnologies (ADPT) might have highlighted stronger performance in the medical sector by ADPT, causing some investors to shift their focus away from CAH.
• Overall, the bearish movement in CAH could be a result of a combination of profit-taking, cautious investor sentiment ahead of the earnings report, and comparative underperformance within the sector.

10.05.2025 - CAH Stock was down 0.5%

• The overall market sentiment is bearish today.
• The bearish movement in CAH stock could be attributed to the announcement of a distribution services agreement between Citius Pharmaceuticals and Cardinal Health. This partnership might have raised concerns among investors about potential competition or changes in Cardinal Health's business strategy, leading to a negative impact on CAH stock price.

30.09.2025 - CAH Stock was up 17.6%

• Cardinal Health (CAH) saw a solid uptrend today, with its stock price rising by +1.72%.
• The positive market sentiment towards CAH is driven by expectations of robust Q1 earnings, especially in its Pharmaceutical and Specialty units.
• CAH has consistently outperformed the market over the past 5 years, with an average annual return of 27.8%, attracting investors seeking stable returns in the healthcare sector.
• The favorable expectations for CAH's financial performance and its strong position in the healthcare industry have fueled the uptick in its stock price today.

30.09.2025 - CAH Stock was up 17.4%

• Cardinal Health (CAH) experienced a strong bullish movement today, with its stock price increasing by +1.72%.
• The positive market movement can be attributed to the expectation of double-digit revenue growth in Q1 FY26, primarily driven by the Pharmaceutical and Specialty units.
• Additionally, the company's consistent outperformance in the market over the past 5 years, with an average annual return of 27.8%, has likely contributed to investor confidence and buying interest in CAH shares.
• Overall, the market seems optimistic about Cardinal Health's future prospects, supported by strong financial performance and growth potential in key business segments.

30.09.2025 - CAH Stock was up 13.0%

• The stock of Cardinal Health saw a notable increase following the positive announcement of its first-quarter 2026 earnings. Adjusted earnings outperformed expectations, and sales witnessed a substantial year-over-year growth.
• Cardinal Health's successful performance in Q1 and the upgraded 2026 EPS forecast point towards a widespread expansion and growing profitability across all sectors, fostering investor confidence.
• Investor optimism towards Cardinal Health has been influenced by its consistent market outperformance in the last 5 years, indicating attractive returns for stakeholders.
• Anticipated double-digit revenue growth in the first quarter of fiscal year 2026, especially in the Pharmaceutical and Specialty units, has further heightened investor confidence in the company's future prospects, encouraging a bullish trend in the stock price.